Keywords: esmo, hears, strong, data, novartis, everolimus, kidney

ESMO hears strong data on Novartis' everolimus in kidney cancer and NET tumors

Article | 22 September 2008

Print This

Updated study findings from the RECORD-1 study show that advanced kidney cancer patients on Novartis' RAD001 (everolimus) had no tumor ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in